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Objective/Background: MicroRNAs (miRNAs) play an important role in diseases develop-
ment. Therefore, human miRNAs may be able to inhibit the survival ofMycobacterium tuber-
culosis (Mtb) in the human host by targeting critical genes of the pathogen. Mutations
within miRNAs can alter their target selection, thereby preventing them from inhibiting
Mtb genes, thus increasing host susceptibility to the disease.
Methods: This study was undertaken to investigate the genetic association of pulmonary
tuberculosis (TB) with six human miRNAs genes, namely, hsa-miR-370, hsa-miR-520d, hsa-
miR-154, hsa-miR-497, hsa-miR-758, and hsa-miR-593, which have been predicted to interact
with Mtb genes. The objective of the study was to determine the possible sequence varia-
tion of selected miRNA genes that are potentially associated with the inhibition of critical
Mtb genes in TB patients.
Results: The study did not show differences in the sequences compared with healthy indi-
viduals without antecedents of TB.
Conclusion: This result could have been influenced by the sample size and the selection of
miRNA genes, which need to be addressed in future studies.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb)
is commonly manifested as a pulmonary disease [1,2].
Estimates indicate that 8.8 million new cases of active TBand 1.4 million deaths are caused by this disease every
year. One third of the human population is latently
infected with Mtb [1,2]. Only approximately 10% of infected
individuals develop the disease, and the remaining 90% do
not progress to clinical TB, although the bacteria remains
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[1,2].
Pathogenic and environmental factors influence host’s
susceptibility to TB and host genetic factors also contribute
to resistance/susceptibility to this disease [3–6].
One of the elements of great importance in gene expres-
sion and regulation is the microRNAs (miRNAs) [7]. Mature
miRNAs (20–22 nt) are formed from long hairpins containing
miRNA precursors (pre-miRNAs; 70–100 nt) as small single-
stranded noncoding RNAs controlling the expression levels
of their target genes by messenger RNA (mRNA) degradation
and protein translation inhibition [7].
There are currently about 1000 human miRNA sequences
available in the miRNA registry representing approximately
60% of all mammalian genes [8]. This indicates that miRNAs
are involved in the fundamental and global functions in
human biology. The miRNAs are also known to be potential
regulators of immune reactivity [9].
Interindividual differences of miRNAs expression are
likely to influence the expression of miRNA target genes, con-
tributing to some changes in human phenotype, conditioning
the evolution, and influencing the susceptibility/resistance to
multiple diseases [9]. The association of miRNAs with multi-
ple diseases, including infectious diseases, has been exten-
sively studied [9–12].
The potential role of miRNAs in the susceptibility and evo-
lution of TB has been studied extensively, with reports indi-
cating changes in several miRNAs, highlighting the potential
role of these molecules in the disease [13–15].
In general, the main alterations related with TB have been
found associated with miRNAs involved in the regulation of
the immune responses and inflammation [13–15].
The potential impact resulting from interactions of human
miRNAs with the expression of Mtb genes has not yet been
explored. Human miRNAs directed at critical genes of Mtb
associated with virulence and survival of the bacteria could
have an important role in the control of the infection.
Mutations in such host miRNA genes could abolish the inhibi-
tion of the expression of critical Mtb genes and increase the
host’s susceptibility to the disease. Guo et al. [16] predicted
26 candidate Mtb genes that are expressed in macrophages
and in the lungs of humans and mice that may be targeted
by 31 human miRNAs [16]. These 31 human miRNAs were
selected as they are expressed in the lungs and macrophages
based on miRNAs expression atlas [17].
In this study, we selected six of the miRNAs predicted by
Guo et al. [16], which target Mtb genes that are responsible
for the virulence and survival of Mtb. These genes have been
reported to be expressed in vivo and/or in macrophages in cul-
ture [18–22]. The objective of this study was to explore possi-
ble polymorphisms within these miRNAs using DNA
sequencing.Materials and methods
Study population
Newly diagnosed adult pulmonary TB patients (n = 33) from
the Hospital Universiti Sains Malaysia (Kubang Kerian,Kelantan, Malaysia) and healthy individuals without TB ante-
cedents (n = 38) were included in the study. A peripheral blood
sample from each participant was collected into a Vacutainer
tube containing the anticoagulant EDTA after obtaining
informed consent from each participant. This study was
approved by the Human Ethics Committee of Universiti
Sains Malaysia.
Selection of miRNAs
Thirty-one humanmiRNAs expressed in the lungs andmacro-
phages and their 26 potential target Mtb genes were previ-
ously predicted by Guo et al. [16]. From this previous study,
we chose to study six human miRNAs, which are predicted
to target five important Mtb genes, using their overexpression
after infection in mice (lung and artificial granuloma) [18,19]
and/or humans (lung, sputum, and macrophage cell lines)
as the main selection criterion [20,22], because they may be
important in virulence/survival of Mtb in vivo.
Primer design
Primers were designed to flank the sites of miRNAs using
NCBI Primer-Basic Local Alignment Search Tool. Hairpin for-
mation, primer dimerization, and self-primer dimerization
were carefully inspected using an online software from inte-
grated DNA Technologies. Each primer set was designed to
amplify the amplicon containing the sequence of specific
miRNA to give a bigger product than the pre-miRNA to ensure
that the full pre-miRNA sequence is obtained. The gene
sequence of pre-miRNAs of each miRNA was obtained from
the NCBI reference sequence [23].
Polymerase chain reaction
Genomic DNA was extracted using the QIAamp DNA blood
mini kit (QIAGEN, Germantown, Maryland, USA). Polymerase
chain reaction (PCR) was performed using specific primers
for each miRNA. The PCR was performed in a 20-lL reaction
mix comprising 10 pmol of each primer (Sigma–Aldrich,
Singapore), 2 lL of 10 · Taq reaction buffer, and 3 lL of
deoxynucleotide triphosphate mix (2.5 mM each; Geneall
Biotechnology, Seoul, Korea).
The mixture was initially heated at 95 C for 3 min to acti-
vate the polymerase. The DNA amplification was performed
for 30 cycles as follows: at 95 C for 30 s, annealing at 58 C
for 30 s, and extension at 72 C for 50 s. The final elongation
step was performed at 72 C for 10 min and the reaction was
held at 4 C. PCR products were purified and sequenced using
the ABI 3130xl genetic analyzer.
DNA sequencing
Termination cycle
The termination cycle of the purified PCR product was carried
out in a final volumeof 10 lL in a 0.5-mL tube containing 3 lL of
the purified PCR product, 3.75 lL of distilled water, 1 lL of pri-
mer (each tube contained only 1 type of primer F1 or R1),
1.75 lL of 5· buffer, and 0.5 lL of big dye (Applied Biosystems,
Carlsbad, California, USA). The cycle sequence amplification
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10 s, 50 C for 5 s, and 60 C for 4 min and a final hold at 4 C.
Ethanol precipitation
To purify the amplification product, ethanol precipitation was
performed after the termination cycle was completed. As
much as 10 lL of the cycle sequence product was transferred
into a 1.5-mL microfuge tube to which 1.5 lL of 2 M sodium
acetate (pH 5.2) and 20 lL of 95% ethanolwere added. Themix-
ture was vortexed and left at room temperature for 30 min.
The mixture was then centrifuged at 6000 rpm (4 C for
40 min) and the supernatant was discarded. Then, 150 lL of
cold 70% ethanol was added into the tube, and the tube was
vortexed and centrifuged at 6000 rpm (4 C for 10 min) and
the step was repeated two more times. The supernatant was
discarded and the tube was dried at 65 C for 10 min in a ther-
mal cycler. To this sample, 10 lL of Hi-Di (Applied Biosystems,
Carlsbad, California, USA) was added and the tube was placed
into the thermal cycler for 3 min at 96 C. Then, the sample
was loaded into 96-well plates and sequenced using the ABI
3130xl genetic analyzer. The sequencing runs up to 16 samples
and yielded read length greater than 500 bp.
Sequencing analysis
Sequence analysis was carried out with the ABI 3130xl genetic
analyzer using the Ultra ‘‘Sep36_POP7’’ sequencing run mod-
ule. The sequence results were analyzed using the BioEditTable 1 – Mtb gene expression during infection.
Mtb genea Human miRNAa
1 Rv0208c/trmB hsa-miR-154d
2 Rv0291/mycP3 hsa-miR-497, hsa-miR-593, hsa
3 Rv0337c/aspC hsa-miR-557
4 Rv0351/grpE hsa-miR-328, hsa-miR-453, hsa
5 Rv0352/dnaJ1 hsa-miR-425-3p
6 Rv0353/hspR hsa-miR-210, hsa-miR-375, hsa
7 Rv0415/thiO hsa-miR-128a, hsa-miR-128b, h
8 Rv0416/thiS hsa-miR-324-5p, hsa-miR-423
9 Rv0432/sodC hsa-miR-453, hsa-miR-638, hsa
10 Rv0440/groEL hsa-miR-370, hsa-miR-486, hsa
11 Rv0462/Lpd hsa-miR-324-3p
12 Rv0500/proC hsa-miR-518a
13 Rv0509/hemA hsa-miR-331, hsa-miR-433, hsa
14 Rv0510/HemC hsa-miR-453, hsa-miR-593
15 Rv0528 hsa-miR-593
16 Rv0555/mend hsa-miR-593
17 Rv0558/ubiE hsa-miR-134, hsa-miR-486
18 Rv0651/rplJ hsa-miR-370, hsa-miR-433, hsa
19 Rv0682/rpsL hsa-miR-370d
20 Rv0685/tuf hsa-miR-593d
21 Rv0707/rpsC hsa-miR-453
22 Rv0709/rpmC hsa-miR-187
23 Rv0714/rplN hsa-miR-614
24 Rv0720/rplR hsa-miR-636, hsa-miR-328, hsa
25 Rv0721/rpsE hsa-miR-525
26 Rv0722/rpmD hsa-miR-671
Note: miRNA = microRNA.
a Mtb genes–miRNA pairs reported by Guo et al [16].
b Mtb gene expressed in vivo in the lungs [18] and/or artificial granuloma
c Mtb gene expressed in the lungs [20], sputum [21], and/or macrophage
d The miRNA–Mtb genes combinations selected for this study.software by comparing them with the sequence of miRNAs
from the miRNA database [8].
Results and discussion
All the Mtb genes predicted by Guo et al. [16] were reported to
be overexpressed in vivo in mice during infection [18,19]
(Table 1). In addition, Mtb genes, Rv0208c/trmB, Rv0682/rpsL,
Rv0291/mycP3, Rv0440/groEL2, and Rv0685/tuf, were reported
to be overexpressed during infection in mice [18,19] and
humans [20–22] (Table 1), suggesting their roles in the viru-
lence/survival of Mtb in vivo, and thus, miRNAs targeting
them were selected for this study.
Table 2 presents the sequences of the pre-miRNAs of each
miRNA selected. Sequences of all the primer sets designed are
showed in Table 3. The designed primers were able to amplify
the target human miRNAs genes with the expected size as
shown in Fig. 1.
The sequence of the six miRNAs in TB patients and
healthy individuals did not show any variations among them
as well as with the reference miRNA sequences retrieved [23].
Genetic association with susceptibility and resistance to
TB has been described previously [3–6]. The presence of differ-
ent polymorphisms in different Toll-like receptors (TLRs) has
been reported to be associated with TB. In the case of TB in
children, the progression of the disease was found to be influ-
enced by the TLR2 variant R753Q [24]. Tumor necrosis factorMiceb Humanc
+ +
-miR-758d + +
+ –
-miR-483 + –
+ –
-miR-423, hsa-miR-636 + –
sa-miR-324-5p, hsa-miR-339 + –
+ –
-miR-654 + –
-miR-520d*d + +
+ –
+ –
-miR-324-3p + –
+ –
+ –
+ –
+ –
-miR-432 + –
+ +
+ +
+ –
+ –
+ –
-miR-639 + –
+ –
+ –
[19] in mice.
cell line [22] in humans.
Table 2 – Pre-miRNA gene sequences.
miRNA Pre-miRNA gene sequence including the mature miRNA (marked in bold) Chromosome
coordinates of the
gene sequence including
the selected miRNA
sequences (GRCh37.p5)
hsa-miR-154 [GenBank:NR_029704]
5 0-GTGGTACTTGAAGATAGGTTATCCGTGTTGCCTTCGCTTTATTTGT
GACGAATCATACACGGTTGACCTATTTTTCAGTACCAA-30
Chr14: 101524492-101526775
hsa-miR-370 [GenBank:NR_029863]
5 0-AGACAGAGAAGCCAGGTCACGTCTCTGCAGTTACACA
GCTCACGAGTGCCTGCTGGGGTGGAACCTGGTCTGTCT-3 0
Chr 14: 101376876-10138150
hsa-miR-497 [GenBank:NR_030178]
5 0-CCACCCCGGTCCTGCTCCCGCCCCAGCAGCACACTGTGGT
TTGTACGGCACTGTGGCCACGTCCAAACCACACTGTGGTGTT
AGAGCGAGGGTGGGGGAGGCACCGCCGAGG-30
Chr17: 6920630-6921941
hsa-miR-520d [GenBank:NR_030204]
5 0-TCTCAAGCTGTGAGTCTACAAAGGGAAGCCCTTTCTGTTGT
CTAAAAGAAAAGAAAG
TGCTTCTCTTTGGTGGGTTACGGTTTGAGA-3 0
Chr19: 54222750-54224036
hsa-miR-593 [GenBank:NR_030324]
5 0-CCCCCAGAATCTGTCAGGCACAGCCAGGCATTG
CTCAGCCCGTTTCCCTCTGGGGGAGCAAGGAGTG
GT GCTGGGTTTG TCTCTGCTGGGGTTTCTCCT-3 0
Chr17: 127721313-127722610
hsa-miR-758 [GenBank:NR_030406]
5 0-CCTGGATACATGAGATGGTTGACCAGAGAGCACACG
CTTTATTTGTGCCGTTTGTG
ACCTGGTCCACTAACCCTCAGTATCTAATGC30
Chr14: 101491757-101493044
Note: miRNA =microRNA.
Table 3 – Primer Used for Polymerase Chain Reaction and Sequencing of Selected miRNAs.
Primer miRNA Label Primer Sequence (5 0–3 0) Size (mer) GC (%) Tm (C) Product size (bp)
Pair 1 hsa-miR-154 F1 GCA TTG AGG TCT GGA TGG CTG 21 57 69 424
R1 GCA CCA TCT CTA GAA ACC TCC C 22 54 65
Pair 2 hsa-miR-370 F2 GCT ACT TGA GGG ATG GGC GA 20 60 68 374
R2 GTC TCT GTG CCT GTT TCC CC 20 60 66
Pair 3 hsa-miR-497 F3 GTC CAA TCT TAC ACT GTG AGC 21 48 59 545
R3 GCC AAT ATT TCT GTG CTG CTA G 22 45 63
Pair 4 hsa-miR-520d F4 CTG GAG ATG GTC TTT GTA TCG G 22 50 64 542
R4 CCT GAC CTG AGA TGA TCT ACC 21 52 60
Pair 5 hsa-miR-593 F5 CTT GGA GTT ACT TCA GGA GC 20 50 58 510
R5 GTA AGC GGT TGG AGG TGT AG 20 55 61
Pair 6 hsa-miR-758 F6 GGA GCT AAC ATC AAC TGC GG 20 55 65 338
R6 CTT CAG AGT CTA ACA GAG TGC 21 48 56
Note: GC (%) = guanosine–cytosine percentage; Tm (C) = melting temperature.
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to TB in a study conducted among Ugandan population [25].
The function and mechanism of miRNAs in the regulation
of innate and acquired immune responses have been
described [26]. Single-nucleotide polymorphisms (SNPs) may
alter the function of miRNAs, and therefore, may influence
the outcome of a particular disease. Most studies on
miRNAs have been carried out in cancer. The importance of
miRNAs in cancer is highlighted by the observation that
approximately 50% of miRNA genes located in cancer-
associated genomic regions or fragile sites [27] are frequently
amplified or deleted in tumorigenesis.A study performed by Wu et al. [28], found that a G! A
mutation in nucleotide 19 downstream of the miRNA let-7e
reduced its expression, and suggested that the mutation
could contribute to tumorigenesis, thus identifying that
genetic polymorphisms in miRNA genes may have therapeu-
tic and diagnostic values [28]. Calin et al. [27] found that the
mutation in two miRNA genes, mir-15 and mir-16, resulted in
nonexpression of these genes and downregulation in chronic
lymphocytic leukemia patients in comparison to normal tis-
sues and lymphocytes, and suggested that these miRNA
genes may be involved in the pathogenesis of the disease.
Previous studies have also confirmed that SNPs in either
A 
       1         2        3         L        4         5         6 
B 
     1        2         3 L         4    5         6 
Fig. 1 – (A) Polymerase chain reaction (PCR) products of all six
primer sets from a tuberculosis patient. (B) PCR product of all
six primer sets from a healthy individual. Note: 1 = hsa-miR-
154; 2 = hsa-miR-370; 3 = hsa-miR-497; L = 100-bp ladder as
reference; 4 = hsa-miR-520d; 5 = hsa-miR-593; 6 = hsa-miR-
758.
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and caused phenotypic changes [29,30].
It has been reported that infection of macrophages with
live mycobacteria (Mtb and Bacillus Calmette–Gue´rin vaccine)
induced an miRNA signature including miR-155, miR-146a,
miR-145, miR-222*, miR-27a, and miR-27b, which potentially
targets genes associated with the immune response [31].
Only two reports have been related to the study of SNPs in
the miRNAs machinery in association with susceptibility and
resistance to TB [32,33]. In one of these studies, a genetic vari-
ant of the DICER protein was associated with resistance to TB
in the Tibetan population [32]. Genetic variants in miRNAs
regulating the TLR pathway were associated with resistance/-
susceptibility in the other study in Tibetan and Han popula-
tions [33].
Our study did not demonstrate any sequence variation in
all the six human miRNAs between newly diagnosed TB
patients and healthy individuals without antecedents of TB.
This may indicate that they may not be involved directly in
susceptibility or resistance to TB. Mutation in miRNAs is not
the only reason for loss of function of miRNAs. There are also
other factors affecting the function of miRNAs. The transcrip-
tion of miRNA gene,mir-124a, was shown to be deactivated by
hypermethylation of its promoter in various human tumors
[34]. The functions of miRNA could also be regulated by the
loss of its binding sites in the target gene. It has been reported
that when chromosomal translocations occur in oncogenes,
the high mobility group A2 (Hmga2) will cause the loss of
let-7 miRNA-binding site in mRNA, thereby promoting onco-
genic transformation and growth in mammalian cells.These studies have shown that disrupting the interaction
between miRNA and its target binding sites can alter the nor-
mal phenotype in mammalian cells [35,36]. Thomson et al.
[37] found that the downregulation of miRNAs in cancer
was not influenced by the reduction in the level of pre-
miRNA transcript but is due to the failure at the Drosha pro-
cessing step [37].
Some of the previous mechanisms, beyond the sequence
of the miRNAs genes, could be operative too in the induction
of resistance or susceptibility to TB.
Conclusion
The negative results of our study could be associated with the
small amount of individuals included or with the selection of
the miRNAs. In addition, the presence of latent infection in
the healthy individuals of the study was not determined,
which could have influenced the results. It might be worth-
while to study the potential genetic variability in the pre-
dicted target sites of the human miRNAs in the genome of
Mtb strains. In future studies with bigger samples, including
infected and noninfected healthy individuals and including
other miRNAs, the potential role of the interaction of
miRNAs and Mtb in the susceptibility/resistance to TB could
be clarified.
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